NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $34.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on NRXP. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. BTIG Research reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Finally, Ascendiant Capital Markets increased their price objective on NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, NRx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

NRx Pharmaceuticals Stock Up 6.2%

Shares of NRXP stock opened at $2.41 on Tuesday. NRx Pharmaceuticals has a 12 month low of $1.15 and a 12 month high of $6.01. The company has a market cap of $67.72 million, a PE ratio of -1.03 and a beta of 1.91. The business’s 50 day moving average is $2.84 and its two-hundred day moving average is $2.89.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. As a group, equities analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter valued at about $39,000. One Wealth Management Investment & Advisory Services LLC lifted its stake in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares during the period. Two Sigma Investments LP lifted its stake in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Geode Capital Management LLC boosted its holdings in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its stake in shares of NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.